Dr. Azzam A. Maghazachi

Dr. Azzam A. Maghazachi |Clyto Access

University of Sharjah, UAE

Organizing Committee Member

Expertise: Cancer Immunotherapy, Malignant Melanomas, Colorectal Cancer, Kidney Cancer, Lung Cancer


Dr. Azzam A. Maghazachi, carried out his post doctoral research in the Kaplan Cancer Center, New York University Medical School, New York, USA. Later he started working as a Professor at 
University of oslo, Norwegian capital of Oslo. He has many honours and awards, Presently he is working as Professor, College of Medicine, University of Sharjah United Arab Emirates.


Title: A New Mechanism of Action for Drugs Used to Treat Multiple Sclerosis for Cancer.

Abstract: Multiple Sclerosis (MS) is an autoimmune disease, whereas cancer develops in immunodeficient individuals. Natural killer (NK) cells stand at the cross road among treatment of autoimmune diseases and immunodeficient diseases. We reported a new mechanism of action for the drug Copaxone (glatiramer acetate or GA; TEVA Inc.). NK cells isolated from patients dosed with GA lysed dendritic cells isolated from the same patients as well killing tumor target cells. Similarly, vitamin D 3 or FTY720 (Gilenya; Novartis) augmented IL-2-activated NK cells lysis of tumor cells. Dimethyl fumarate (DMF;Biogen Inc.) is a new drug for treating MS patients. We have examined the effects of DMF and the metabolite monomethyl fumarate (MMF) on various activities of NK cells. Results: We demonstrate that MMF induces resting CD56 + NK cell lysis of the NK-sensitive K562 cells and the NK-resistant RAJI cells. More recently, we observed that GA, MMF and DMF up-regulate the expression of CCR10 on the surface of activated NK cells. This is corroborated with the ability of NK cells to migrate towards the concentration gradients of CCR10 ligands, namely CCL27 and CCL28. Conclusions: Our observations are the first to show that drugs used to treat multiple sclerosis can be used to direct the anti-tumor effector cells towards the sites of tumor growth, particularly those secreting the chemokine CCL27 such as melanomas or squamous cell carcinoma, or those secreting CCL28 such as colorectal carcinoma. Hence, drugs used to treat autoimmune diseases can be used to harness NK cells for the purpose of using them in cancer immunotherapy. Clinical protocols using this novel strategy will be discussed.

Related Conferences :

International Conference on Cancer Care and Cure